biotech · Clostridium Difficile Infection · Autism Spectrum Disorder · FNCHQ
Finch Therapeutics Group
Finch Therapeutics is a biotech organization headquartered in Somerville, USA. It trades on NYSE under ticker FNCHQ. Primary therapeutic focus areas include Clostridium Difficile Infection, Autism Spectrum Disorder, Recu
Somerville, USA HQ
15 Employees
Public company Type
FNCHQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Somerville, USA
- Employees
- 15
- Programs
- 5
- Drugs
- 2
- Patents
- 33
CP101
Phase 3 · mab · Recurrent C. Difficile Infection
CP101 for Recurrent C. Difficile Infection is a Phase 3 program (mab) at Finch Therapeutics Group with 1 ClinicalTrials.gov record(s).
Internal code FIN-CDI-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Finch Therapeutics Group
- Phase
- Phase 3
- Modality
- mab
- Indication
- Recurrent C. Difficile Infection
- Status
- terminated
- Trials
- 1